Intrexon reported $-14122000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agenus AGEN:US $ -43.28M 8.94M
Amgen AMGN:US $ 3004M 337M
Arrowhead Research ARWR:US $ -70306000 114.46M
AstraZeneca AZN:LN 3562M 625M
Bluebird Bio BLUE:US $ -99.42M 19.92M
Bristol Myers Squibb BMY:US $ 5780M 8M
Chemocentryx CCXI:US $ -30.55M 6.67M
Gilead Sciences GILD:US $ 2585M 837M
GlaxoSmithKline GSK:LN 2447M 673M
Karyopharm Therapeutics KPTI:US $ -42759000 8.35M
Macrogenics MGNX:US $ -38931000 24.79M
Mannkind MNKD:US $ -23.55M 1.63M
Novartis NOVN:VX SF 4660M 108M
Peregrine Pharmaceuticals PPHM:US $ 2.49M 1.8M
Sangamo Biosciences SGMO:US $ -42.85M 0.42M
Thermo Fisher Scientific TMO:US $ 2861M 821M
Veracyte VCYT:US $ -0.94M 7.75M
Xencor XNCR:US $ -25.78M 54.42M
YTE INCY:US $ 276.8M 132.69M
Ziopharm Oncology ZIOP:US $ -8.4M 1.21M